Mark Shearman

Mark S. Shearman, Ph.D.

Chief Executive Officer

  • Chief Scientific Officer/Executive Vice-President, Editas Medicine
  • Chief Scientific Officer, Applied Genetic Technologies Corporation
  • Senior Vice-President, Neurology, EMD Serono
  • Executive Director, Neuroscience, Merck & Co.
  • Senior Director, Neuroscience, Merck Sharp & Dohme, UK
  • Post-doctoral research fellowships at Max-Planck Institute for Biochemistry, Germany and Kobe University School of Medicine, Japan
  • D. Neuroscience, University of Nottingham, UK
  • Sc.(Hons) University of Bristol, UK
  • CNS drug discovery, cell and gene therapy, gene editing
  • Neurodegenerative diseases, Multiple Sclerosis, Ophthalmology, Immuno-Oncology, Sickle-cell disease